04:42 | 26th July 2017

World News:

Thu 22 Sep, 2011
By Editor


“WHO will be working with countries to use the new findings to protect more men and women from HIV infection.”

Latest Headlines

Youth Invited to Design Social Media Strategy for UNAIDS

The United Nations has invited young people to create and shape the new UN strategy on youth and HIV/AIDS through an online collaborative project launched Tuesday, according to an article on the UN website


Blood donation center rejects straight man because he 'appeared' gay

A 22-year-old straight man was refused the right to donating blood after staff at a blood bank believed the man ‘seemed’ gay.


Nicki Minaj and Ricky Martin new faces of MAC Viva Glam HIV/AIDS campaign

Nicki Minaj and Ricky Martin have been announced as the faces of the 2012 MAC Viva Glam campaign to fight HIV/AIDS.


UNAIDS and WHO hail new results for Once - daily pill for HIV Negative people

New data from studies in Kenya, Uganda and Botswana confirm major role of antiretroviral medicine in preventing heterosexual HIV transmission


UNAIDS and WHO hail new results for Once - daily pill for HIV Negative people

UNAIDS and WHO hail new results showing that a once-daily pill for HIV-negative people can prevent them from acquiring HIV.

New data from studies in Kenya, Uganda and Botswana confirm
major role of antiretroviral medicine in preventing heterosexual HIV transmission Results announced from two studies
reveal that a daily antiretroviral tablet taken by people who do
not have HIV infection can reduce their risk of acquiring HIV by up to 73%. Both daily tenofovir and daily tenofovir/emtricitabine taken as preventive medicine (PrEP - preexposure prophylaxis) can prevent heterosexual transmission of HIV from men to women and from women to men. The Partners PrEP trial, conducted by the University of Washington’s International Clinical Research Center, followed 4758 sero-discordant
couples (in which one person had HIV infection and the other did not) in Kenya and Uganda.



Couples received counselling and free male and female condoms. The uninfected partner took a once-daily tenofovir tablet or a tenofovir/emtricitabine tablet or a placebo pill. There were 62% fewer HIV infections in the group receiving tenofovir and 73% fewer HIV infections in the group that took
tenofovir/emtricitabine than in the group receiving the placebo.
The TDF2 trial, conducted by the United States Centers for Disease Control, followed 1200 men and women in Botswana who received either a once-daily tenofovir/ emtricitabine tablet or a placebo pill. The antiretroviral tablet reduced the risk of acquiring HIV infection by roughly 63% overall in the study population of uninfected heterosexual men and women.
“This is a major scientific breakthrough which re-confirms
the essential role that antiretroviral medicine has to play in the AIDS response,” said Michel Sidibé, Executive Director of the Joint United Nations Programme on HIV/AIDS (UNAIDS). “These studies could help us to reach the tipping point in the HIV epidemic.” The medicines are available
generically in many countries at prices as low as US$ 0.25 per tablet. In November 2010, the iPrEx trial among men who have sex with men in six countries reported a 44% reduction in HIV transmission among those who took a daily tenofovir/
emtricitabine tablet. “Effective new HIV prevention tools are urgently needed, and these studies could have enormous
impact in preventing heterosexual transmission,” said Dr Margaret Chan, WHO’s Director-General. “WHO
will be working with countries to use the new findings to protect more men and women from HIV infection.”

UNAIDS and WHO have already been working with countries in sub- Saharan Africa, Latin America and Asia to explore the potential role of pre-exposure prophylaxis in HIV prevention. This news will encourage more people to get tested for HIV,
discuss HIV prevention options with their partners and access essential HIV services.

 

Back to previous page

cialis